This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of dimethyl fumarate
MSMED_DIMETHYL_FUMARATE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
326 |
4. Check minimum number of events
Min. number of events
3
|
326 |
5. Include endpointsNone |
326 |
6. Filter based on genotype QC (FinnGen only) |
309 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of dimethyl fumarate
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 309 | 250 | 59 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.03 |
| Median age at first event (years) | 41.21 | 40.84 | 42.77 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 326
- Matched controls
- 3260
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
326
25
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
12304.2
307.7
323
16
L04AX07
ATC
dimethyl fumarate; oral
2794.0
307.7
266
5
L03AB07
ATC
interferon beta-1a; parenteral
314.1
307.7
168
11
109
Kela drug reimbursment
Multiple sclerosis
12304.2
307.7
323
16
N07XX09
ATC
[U] dimethyl fumarate
+∞
307.7
326
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
307.7
326
15
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
41.9
272.0
222
158
H46
ICD-10 Finland
Optic neuritis
99.1
202.6
107
16
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
83.8
168.6
91
15
TAB00
NOMESCO Finland
Lumbar puncture
23.9
154.9
129
87
L03AX13
ATC
glatiramer acetate; parenteral
265.2
134.0
129
8
N86
ICPC
Multiple sclerosis
367.7
124.4
118
5
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
32.9
95.7
64
24
XCK00
NOMESCO Finland
Perimetry
20.7
93.8
77
48
XA800
NOMESCO Finland
Neuropsychological investigation
14.8
88.9
90
82
L04AA31
ATC
[U] teriflunomide
547.4
87.5
83
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
40.1
81.7
51
15
L03AB08
ATC
interferon beta-1b; parenteral
478.3
78.4
75
*
M03BX01
ATC
baclofen; systemic
26.3
76.3
55
25
ZX120
NOMESCO Finland
Intravenous
11.1
75.5
94
115
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
31.9
73.2
49
18
G04BD12
ATC
mirabegron; oral
12.9
72.9
79
79
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.2
69.5
103
156
XKD00
NOMESCO Finland
Uroflowmetry
13.0
64.3
68
65
R1250
NOMESCO Finland
Evaluation of functional capability
19.5
61.2
50
30
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
25.3
60.7
44
20
N04BB01
ATC
amantadine; oral
113.4
60.4
64
7
164
Kela drug reimbursment
Fingolimod
111.2
59.3
63
7
2AB04, ,
NOMESCO Finland
224.4
55.9
56
*
353
Kela drug reimbursment
Cladribine and fingolimod
93.8
50.7
55
7
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
11.5
46.6
52
53
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.6
43.7
43
36
L04AA27
ATC
[U] fingolimod
123.4
40.8
43
*
H02AB04
ATC
methylprednisolone; systemic
5.4
38.1
93
224
R20.2
ICD-10 Finland
Paraesthesia of skin
5.6
33.5
74
162
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
189.1
33.4
34
*
G04BD08
ATC
solifenacin; oral
11.4
33.0
36
35
N06BA07
ATC
modafinil; oral
69.2
32.8
37
6
G04BD09
ATC
trospium; oral
51.9
31.3
37
8
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.6
30.5
67
145
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.2
28.1
96
296
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
26.4
25
*
C10AC01
ATC
colestyramine; oral
9.7
25.5
31
35
R4110
NOMESCO Finland
Physiotherapy
3.5
24.7
123
484
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.2
23.1
52
114
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.8
22.9
45
87
Z3226
NOMESCO Finland
Physiotherapist
3.7
22.2
90
308
UKC02
NOMESCO Finland
Cystoscopy
4.9
22.1
54
127
TKC22
NOMESCO Finland
Catheterisation instruction
46.9
21.7
26
6
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.4
21.1
45
94
Z3231
NOMESCO Finland
Registered nurse
3.1
20.1
123
538
L04AG12
ATC
ofatumumab; parenteral
+∞
20.0
19
*
Z2445
NOMESCO Finland
Psychologist
5.2
19.5
43
92
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
18.9
18
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
17.6
18.7
29
18
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
35.2
18.2
23
7
L04AK02
ATC
teriflunomide; oral
189.9
17.7
18
*
4AA23, ,
NOMESCO Finland
189.9
17.7
18
*
N03AE01
ATC
clonazepam; systemic
5.2
17.1
37
78
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
6.0
16.8
31
56
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
16.8
16
*
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
16.8
16
*
H53.2
ICD-10 Finland
Diplopia
7.4
16.8
25
36
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.8
16.4
40
93
L04AA40
ATC
cladribine; oral
63.3
15.9
18
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.5
15.8
27
45
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
12.1
15.6
28
25
G04BD04
ATC
oxybutynin; oral, transdermal
5.9
14.6
27
49
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
18.0
14.5
22
13
R4150
NOMESCO Finland
Neuropsychological rehabilitation
14.3
14.5
24
18
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.8
14.2
34
78
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
6.9
13.8
22
34
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
145.8
13.6
14
*
N05CF01
ATC
zopiclone; oral
2.5
13.3
114
573
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
41.9
13.3
16
*
XKC03
NOMESCO Finland
Water cystometry
11.7
13.3
24
22
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.7
13.2
25
25
R4120
NOMESCO Finland
Occupational therapy
4.2
13.0
37
97
N03AX12
ATC
[U] gabapentin; oral
2.9
12.8
72
292
G04BD11
ATC
fesoterodine; oral
25.5
12.6
17
7
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
9.6
12.5
25
28
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.1
12.3
35
92
G04BD07
ATC
tolterodine; oral
9.5
12.0
24
27
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
11.5
11
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
124.2
11.5
12
*
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.7
11.2
22
24
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
62.1
10.7
12
*
L04AX09
ATC
diroximel fumarate; oral
+∞
10.5
10
*
TKC20
NOMESCO Finland
Catheterisation of bladder
5.2
10.4
22
45
G04CA02
ATC
tamsulosin; oral
3.8
10.3
33
94
Z2221
NOMESCO Finland
Medical doctor
2.2
9.7
117
666
H53.1
ICD-10 Finland
Subjective visual disturbances
3.4
9.7
37
119
SPAT1229
SPAT
Assessment of need for aid
5.0
9.7
21
44
N39.4
ICD-10 Finland
Other specified urinary incontinence
4.1
9.6
27
70
R35
ICD-10 Finland
Polyuria
4.2
9.5
26
66
N02BF01
ATC
gabapentin; oral
3.2
9.4
39
132
A06AD11
ATC
lactulose; oral
3.3
9.3
36
117
N29
ICPC
Neurological sympt/complt other
8.7
9.2
19
23
N03AX16
ATC
[U] pregabalin
2.3
8.6
81
414
R33
ICD-10 Finland
Retention of urine
7.7
8.6
19
26
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
8.4
50
207
G04BE03
ATC
sildenafil; oral
+∞
8.4
8
*
J01EA01
ATC
trimethoprim; systemic
2.1
8.3
100
565
L28
ICPC
Limited function/disability (L)
2.9
8.1
41
156
XKD03
NOMESCO Finland
Urethral pressure profilometry
11.2
7.9
14
13
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
18.9
7.6
11
6
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
81.9
7.4
8
*
G04CA01
ATC
alfuzosin; oral
3.9
7.3
22
60
4AA36, ,
NOMESCO Finland
+∞
7.3
7
*
A28
ICPC
Limited function/disability NOS
3.1
7.2
30
102
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
5.9
6.9
18
32
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
40.9
6.8
8
*
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
17.1
6.8
10
6
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
23.1
6.7
9
*
N02BF02
ATC
pregabalin; oral
3.1
6.7
29
101
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
7.6
6.5
14
19
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
+∞
6.3
6
*
XCK10
NOMESCO Finland
Photography of fundus of eye
3.0
6.2
27
94
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
12.8
6.1
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
93
55
23.26
117.16
1.2
1.1
—
—
—
0
0
233
698
9.20
84.73
5.2
2.6
—
—
—
0
0
301
1246
19.46
77.71
21.0
5.5
9.53
7.80
%
26.03
301
1185
300
1244
18.70
77.05
20.7
5.2
2.86
2.79
%
0.21
300
1179
301
1285
18.51
73.94
20.4
5.1
62.14
56.46
%
21.95
301
1222
302
1295
19.09
73.84
20.7
5.3
23.66
29.73
%
27.91
302
1237
189
549
6.81
67.42
4.7
2.2
0.06
0.25
e6/l
3.58
183
400
75
81
11.73
65.40
1.8
1.6
0.01
0.01
iu/ml
—
6
11
109
197
7.81
62.43
4.1
2.4
9.66
10.16
g/l
0.98
101
184
118
299
5.62
46.43
3.6
2.1
0.66
0.89
e6/l
0.54
79
157
100
285
4.62
32.99
3.9
2.1
2.81
3.74
e6/l
0.52
61
143
217
1075
4.05
32.37
2.4
2.2
94.80
72.12
nmol/l
18.58
209
1014
35
37
10.48
30.27
1.1
1.0
—
—
—
0
0
228
1248
3.75
27.49
7.8
4.0
0.00
0.00
estimate
0.50
47
258
228
1258
3.70
26.92
5.8
2.9
0.00
0.00
estimate
-0.00
48
252
227
1250
3.69
26.87
5.9
2.9
0.00
0.00
estimate
-0.00
48
271
37
16
25.91
26.78
2.6
2.9
—
—
—
0
0
27
29
10.06
22.95
1.0
1.1
—
—
—
0
0
51
111
5.26
22.84
1.3
1.3
—
—
—
0
0
27
33
8.83
20.81
1.0
1.1
—
—
—
0
0
26
32
8.74
19.91
1.0
1.1
—
—
—
0
0
30
20
16.39
18.84
1.0
1.0
—
—
—
0
0
326
2870
+∞
16.88
13.8
9.6
62.85
68.39
umol/l
14.30
326
2870
23
18
13.65
13.63
3.5
2.9
52.86
45.94
%
—
14
7
30
67
4.83
12.88
1.0
1.2
17.52
226.85
e6/l
1.08
25
53
30
67
4.83
12.88
1.0
1.1
13.79
4.56
e6/l
1.75
24
50
22
18
13.01
12.81
1.1
1.1
1786.59
1720.28
miu/ml
0.07
22
18
22
20
11.71
12.23
1.0
1.1
0.90
1.08
u/l
—
5
12
16
7
23.93
11.68
5.3
2.1
—
—
—
0
0
53
196
3.03
11.05
2.8
1.6
—
—
—
0
0
208
2578
0.47
9.38
2.7
3.0
1.20
1.24
mmol/l
0.42
196
2464
23
54
4.51
9.28
3.8
3.6
3.36
4.35
e9/l
1.71
23
54
52
210
2.76
9.19
1.3
1.2
—
22.98
—
0
11
23
55
4.42
9.07
3.9
3.7
61.22
58.29
%
0.63
23
55
145
928
2.01
8.59
3.7
3.0
25.99
28.21
u/l
0.61
137
890
223
2676
0.47
8.47
3.0
3.3
1.61
1.49
mmol/l
3.24
206
2571
227
2705
0.47
8.37
3.1
3.6
2.98
2.93
mmol/l
0.33
211
2592
295
2485
2.97
8.21
25.0
11.2
13.43
14.13
%
3.25
295
2454
172
1188
1.95
8.00
3.6
4.9
9.15
10.02
umol/l
0.99
165
1126
227
2683
0.49
7.43
3.0
3.4
4.94
4.83
mmol/l
1.05
213
2582
53
247
2.37
6.92
2.8
2.2
2289.38
2837.59
u/l
—
6
103
293
2511
2.65
6.91
9.9
7.7
103.30
94.57
ml/min/173m2
20.40
270
2047
145
991
1.83
6.58
7.1
2.9
—
—
—
0
0
10
8
12.84
6.12
1.0
1.8
—
—
—
0
0
8
5
16.34
5.43
1.8
3.4
—
—
—
0
0
326
3145
+∞
4.66
30.3
14.2
41.17
40.57
%
2.77
316
3013
326
3149
+∞
4.48
30.0
14.3
137.43
136.33
g/l
1.11
326
3122
97
647
1.71
4.45
8.7
3.2
0.00
0.01
estimate
0.80
47
256
164
1262
1.60
4.23
3.1
3.8
6.19
6.32
mmol/l
0.42
154
1127
115
854
1.54
3.26
3.2
3.9
39.05
37.51
g/l
2.27
105
810
300
2770
2.04
3.14
9.4
9.3
21.03
18.21
mg/l
0.61
199
2088
219
1870
1.52
3.12
4.3
6.2
67.57
71.91
u/l
1.56
207
1775
286
2609
1.78
2.99
7.7
8.8
3.90
3.91
mmol/l
0.26
277
2530
285
2600
1.76
2.95
7.6
8.7
139.94
139.61
mmol/l
1.89
278
2533
202
2294
0.69
2.69
3.0
4.0
36.67
37.59
mmol/mol
0.78
193
2199
44
270
1.73
2.67
2.3
2.2
5.06
6.16
umol/l
0.32
34
233
9
25
3.67
2.59
1.0
1.6
—
—
—
0
0
226
2486
0.70
2.17
2.5
3.3
5.53
5.63
mmol/l
0.84
215
2346
14
274
0.49
1.90
1.2
1.5
—
—
—
0
0
31
475
0.62
1.81
3.4
3.8
5.06
11.60
mg/mmol
0.67
19
298
7
25
2.84
1.66
1.0
1.1
—
—
—
0
0
7
25
2.84
1.66
1.0
1.1
—
—
—
0
0
96
772
1.35
1.61
1.4
1.5
—
—
—
0
0
7
26
2.73
1.59
1.0
1.1
—
—
—
0
0
7
26
2.73
1.59
1.0
1.1
—
—
—
0
0
7
26
2.73
1.59
1.0
1.1
—
—
—
0
0
10
204
0.47
1.55
1.5
1.4
—
—
—
0
0
26
397
0.63
1.50
1.2
1.5
—
—
—
0
0
13
234
0.54
1.40
1.3
1.4
—
—
—
0
0
13
234
0.54
1.40
1.3
1.4
—
—
—
0
0
13
233
0.54
1.38
1.3
1.4
—
—
—
0
0
13
233
0.54
1.38
1.3
1.4
—
—
—
0
0
17
98
1.78
1.33
1.5
1.4
22.05
21.22
u/l
0.04
12
82
0
40
0.00
1.33
0.0
2.0
—
0.99
—
0
35
8
159
0.49
1.28
1.4
1.7
—
—
—
0
0
15
247
0.59
1.20
1.4
1.5
—
—
—
0
0
107
1244
0.79
1.18
2.2
2.3
—
—
—
0
0
10
184
0.53
1.17
1.6
1.5
—
—
—
0
0
40
525
0.73
1.08
1.3
1.3
2.11
8.98
u/ml
2.17
16
233
234
2484
0.79
1.06
3.4
3.9
—
—
—
0
0
7
133
0.52
1.01
1.1
1.5
—
—
—
0
0
129
1447
0.82
0.97
2.4
2.9
102.73
65.82
ug/l
0.68
121
1386
9
153
0.58
0.91
2.6
1.9
—
—
—
0
0
24
174
1.41
0.79
8.5
6.6
105.54
105.01
mmol/l
0.27
24
174
83
715
1.22
0.78
1.7
2.8
2.36
2.35
mmol/l
0.44
76
666
0
28
0.00
0.76
0.0
1.8
—
—
—
0
0
7
40
1.77
0.71
1.0
1.2
—
—
—
0
0
7
40
1.77
0.71
1.0
1.2
—
—
—
0
0
14
204
0.67
0.71
1.9
5.4
0.91
1.02
mmol/l
0.96
14
189
28
214
1.34
0.69
2.4
2.2
25.09
33.77
u/l
1.11
22
185
49
586
0.81
0.68
1.9
1.8
—
—
—
0
0
23
171
1.37
0.67
1.3
1.7
—
—
—
0
0
5
29
1.74
0.64
1.2
1.2
—
—
—
0
0
24
182
1.34
0.63
1.3
1.3
118.20
260.17
miu/ml
—
10
92
267
2573
1.21
0.63
4.6
4.7
1.65
2.14
mu/l
0.55
255
2465
14
96
1.48
0.62
1.1
1.3
—
—
—
0
0
8
50
1.61
0.61
1.0
2.3
2.51
2.62
g/l
—
8
50
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
8
52
1.55
0.60
1.0
2.3
6.09
6.90
g/l
—
8
52
8
52
1.55
0.60
1.0
2.3
—
—
—
0
0
8
52
1.55
0.60
1.0
2.3
3.29
3.50
g/l
—
8
52
8
55
1.47
0.56
1.0
1.3
—
110.20
—
0
15
10
65
1.56
0.56
1.0
1.2
—
—
—
0
0
52
604
0.83
0.55
1.6
1.7
0.54
0.67
mg/l
0.53
40
443
9
134
0.66
0.53
1.0
1.6
—
—
—
0
0
6
40
1.51
0.52
1.0
2.5
41.52
40.91
g/l
—
6
40
9
65
1.40
0.51
1.0
1.2
—
—
—
0
0
7
106
0.65
0.49
1.1
1.6
—
—
—
0
0
47
545
0.84
0.49
1.8
2.0
2.68
2.93
mg/l
0.23
37
486
18
232
0.76
0.48
3.3
3.3
28.00
31.26
%
0.74
13
179
8
119
0.66
0.46
2.1
1.8
—
—
—
0
0
35
414
0.83
0.46
1.6
1.6
—
—
—
0
0
37
435
0.83
0.45
1.7
1.7
—
—
—
0
0
48
416
1.18
0.45
1.3
1.6
551.53
58594169.34
pmol/l
1.07
43
384
21
166
1.28
0.44
1.3
1.7
—
—
—
0
0
13
95
1.38
0.44
2.2
1.9
8.60
6.76
iu/l
—
5
36
5
31
1.62
0.43
1.6
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
2.0
—
3.84
—
0
16
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
16
0.00
0.41
0.0
2.5
—
117.94
—
0
16
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
40
345
1.18
0.40
1.7
2.7
15.07
491.92
ng/l
1.09
15
170
55
616
0.87
0.38
1.5
1.6
1.58
1.43
mmol/l
0.43
46
555
47
531
0.87
0.37
1.2
1.3
11.54
24.53
iu/ml
—
8
178
6
42
1.44
0.35
2.7
1.7
213.50
187.94
ug/l
—
6
37
6
43
1.40
0.35
1.0
1.0
—
—
—
0
0
6
43
1.40
0.35
1.2
1.7
—
—
—
0
0
80
735
1.12
0.34
1.3
1.3
0.51
2.42
u/ml
1.67
14
200
6
46
1.31
0.33
1.2
1.7
—
—
—
0
0
83
768
1.11
0.32
1.5
1.7
100.38
97.73
pmol/l
0.19
42
446
79
853
0.90
0.31
4.9
4.8
1.22
1.22
mmol/l
0.30
71
797
11
84
1.32
0.30
2.9
8.1
22.27
24.77
mmol/l
1.50
11
78
7
56
1.26
0.29
1.1
1.6
—
—
—
0
0
7
56
1.26
0.29
1.0
1.3
—
1.23
—
0
6
8
109
0.73
0.29
1.4
1.6
1.07
1.18
g/l
—
8
103
30
343
0.86
0.29
1.7
1.7
—
—
—
0
0
22
187
1.19
0.27
1.5
1.4
—
—
—
0
0
23
197
1.18
0.26
1.0
1.0
—
—
—
0
0
46
417
1.12
0.26
1.4
1.4
18.99
20.86
nmol/l
0.44
41
377
34
304
1.13
0.24
1.7
2.0
16.38
15.72
umol/l
0.19
29
284
20
232
0.85
0.23
5.1
4.5
—
—
—
0
0
78
828
0.92
0.22
1.6
1.6
—
—
—
0
0
199
1937
1.07
0.22
2.3
3.4
6.75
8.26
mm/h
2.65
185
1831
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
3.4
—
127.50
—
0
10
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
95.33
—
0
6
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
115.67
—
0
6
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
13
0.00
0.21
0.0
1.0
—
147.23
—
0
13
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
68
722
0.93
0.19
2.0
2.1
—
—
—
0
0
15
175
0.85
0.19
1.2
2.3
0.25
0.24
g/l
0.16
15
169
65
691
0.93
0.19
1.6
2.5
211.84
17.60
ng/l
0.62
27
278
6
53
1.13
0.19
1.5
1.4
—
—
—
0
0
92
963
0.94
0.18
5.1
5.5
1.23
1.22
mmol/l
1.03
81
830
12
101
1.20
0.17
1.1
1.4
—
—
—
0
0
20
177
1.14
0.16
1.5
1.9
91.80
80.68
ml/min/173m2
—
5
62
27
295
0.91
0.14
1.3
1.2
72.81
185.14
iu/ml
—
9
122
62
651
0.94
0.13
1.8
1.9
—
—
—
0
0
29
267
1.09
0.13
1.4
1.8
—
—
—
0
0
15
133
1.13
0.12
10.8
7.7
124.47
122.45
g/l
0.15
15
128
11
95
1.16
0.12
1.1
1.1
—
—
—
0
0
14
155
0.90
0.09
1.4
1.5
—
—
—
0
0
5
60
0.83
0.08
1.2
1.1
—
—
—
0
0
5
63
0.79
0.08
1.0
1.1
—
—
—
0
0
7
64
1.10
0.08
1.4
2.9
53.79
55.73
%
—
7
64
7
64
1.10
0.08
2.7
1.8
—
—
—
0
0
23
215
1.08
0.08
1.8
3.1
20.20
22.93
%
—
10
59
6
74
0.81
0.07
1.3
1.9
—
—
—
0
0
8
76
1.05
0.07
1.0
1.6
—
—
—
0
0
9
84
1.07
0.07
1.1
1.2
—
29.17
—
0
15
17
183
0.93
0.06
1.8
2.6
—
—
—
0
0
14
152
0.92
0.06
12.9
7.4
2.47
0.93
mmol/l
—
6
114
75
768
0.97
0.06
2.0
6.7
1.00
1.05
inr
1.37
23
260
220
2218
0.98
0.05
4.0
4.2
14.62
14.30
pmol/l
1.21
207
2108
71
722
0.98
0.03
1.7
2.2
50.31
57.25
u/l
1.33
64
681
12
126
0.95
0.00
3.4
3.6
72.00
74.24
ng/l
0.05
12
118
10
102
0.98
0.00
1.1
2.2
—
—
—
0
0
16
163
0.98
0.00
1.8
2.0
0.60
0.57
ug/l
—
8
66
25
253
0.99
0.00
1.7
2.0
25.84
25.87
%
0.00
18
220
15
154
0.97
0.00
12.3
7.3
5.07
5.08
kpa
0.01
15
146
15
154
0.97
0.00
12.3
7.3
12.91
13.79
kpa
0.22
15
147
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
79
1.01
-0.00
1.6
2.3
89.15
62.63
ng/l
—
8
71
0
8
0.00
-0.00
0.0
1.1
—
203.13
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.0
—
7.18
—
0
9
7
79
0.88
-0.00
1.4
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.20
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
114.38
—
0
8
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
8
88
0.91
-0.00
1.8
5.0
25.74
24.66
mmol/l
—
8
88
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
6
60
1.00
-0.00
1.8
1.8
13.00
13.22
%
—
6
60
0
6
0.00
-0.00
0.0
1.5
—
17.00
—
0
6
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
6.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
16.85
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_DIMETHYL_FUMARATE – Use of dimethyl fumarate
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).